Transforming growth factor beta as a therapeutic target in systemic sclerosis. - Wikidata - awgldk - TriplyDB

Transforming growth factor beta as a therapeutic target in systemic sclerosis.

Transforming growth factor beta as a therapeutic target in systemic sclerosis.

http://www.wikidata.org/entity/Q37428739

about

The immune pathogenesis of scleroderma: context is everything Immunotherapy of systemic sclerosis Role of EMT in Metastasis and Therapy Resistance Recent developments in myofibroblast biology: paradigms for connective tissue remodeling The role of the myofibroblast in tumor stroma remodeling Molecular Cues Guiding Matrix Stiffness in Liver Fibrosis Gene expression profiling offers insights into the role of innate immune signaling in SSc A synthetic PPAR-γ agonist triterpenoid ameliorates experimental fibrosis: PPAR-γ-independent suppression of fibrotic responses Micro RNA-98 suppresses interleukin-10 in peripheral B cells in patient post-cardio transplantation.PPARγ downregulation by TGFß in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis Egr-1 induces a profibrotic injury/repair gene program associated with systemic sclerosis.Tyrosine kinases in inflammatory dermatologic disease.Mutations in fibrillin-1 cause congenital scleroderma: stiff skin syndrome.Fibrosis: recent advances in myofibroblast biology and new therapeutic perspectives.Proinflammatory and profibrotic mediators: principal effectors of leiomyoma development as a fibrotic disorder.Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma?Chitinase 1 is a biomarker for and therapeutic target in scleroderma-associated interstitial lung disease that augments TGF-β1 signaling.Evidence for early fibrosis and increased airway resistance in bone marrow transplant recipient mice deficient in MMP12.PAI-1-regulated miR-21 defines a novel age-associated fibrogenic pathway in muscular dystrophy.Fn14, a Downstream Target of the TGF-β Signaling Pathway, Regulates Fibroblast Activation.Transforming growth factor-β neutralizing antibodies inhibit subretinal fibrosis in a mouse model Regulation of Matrix Remodeling by Peroxisome Proliferator-Activated Receptor-γ: A Novel Link Between Metabolism and Fibrogenesis.Matrix-dependent perturbation of TGFβ signaling and disease Levels of adiponectin, a marker for PPAR-gamma activity, correlate with skin fibrosis in systemic sclerosis: potential utility as biomarker?CD109, a TGF-β co-receptor, attenuates extracellular matrix production in scleroderma skin fibroblasts.Molecular Mechanism Responsible for Fibronectin-controlled Alterations in Matrix Stiffness in Advanced Chronic Liver Fibrogenesis.Toll-like receptor 4 signaling augments transforming growth factor-β responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma.20S-hydroxyvitamin D3, noncalcemic product of CYP11A1 action on vitamin D3, exhibits potent antifibrogenic activity in vivo The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathways The adipokine adiponectin has potent anti-fibrotic effects mediated via adenosine monophosphate-activated protein kinase: novel target for fibrosis therapy.Unraveling the signaling pathways promoting fibrosis in Dupuytren's disease reveals TNF as a therapeutic target Fibrocytes: emerging effector cells in chronic inflammation Comparative Transcriptome Analysis Identifies CCDC80 as a Novel Gene Associated with Pulmonary Arterial Hypertension.OX40L blockade protects against inflammation-driven fibrosis.The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis A peptide derived from endostatin ameliorates organ fibrosis.Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro.The primary care physician in the early diagnosis of systemic sclerosis: the cornerstone of recognition and hope.Reassessing the Role of the Active TGF-β1 as a Biomarker in Systemic Sclerosis: Association of Serum Levels with Clinical Manifestations.Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.

P2860

Q24633658-9822F090-1C5A-4FF5-BD4B-9F7AC539B477 Q24634395-FEC58E0C-FCE2-4180-9A00-7FD0EFC033DF Q26772923-DA5448C3-190D-4396-8AC7-C04DE2100E41 Q26863751-0E0E9C9A-7F34-475B-9962-FF8E1E2E5FBB Q26997815-80012351-CAE5-412A-A074-B6DCA551A5C8 Q28077583-3334D8DC-8419-4D0E-83A1-C49C89A9075B Q28083733-2A915A42-5D32-42F5-9161-540170FFC1AC Q33637862-D7734B87-45B7-4E28-90E3-CA596B928F88 Q33709652-11F6B87F-2E4E-43E1-A71C-B96EC721D2C2 Q33745028-FA1DB14F-08A5-4C84-9137-9F1281A6FCE9 Q34023076-5009EC3D-E101-49B2-BBC7-9283CA02999E Q34166503-03489260-11A5-459C-A4A4-69723204932C Q34192783-057BF3D5-6FBF-41F7-8CE5-4FC026A05AA9 Q34389512-BA271D4B-6B72-4692-B18C-23CC9D0F25AF Q34674982-A0CB0C13-AAC2-40A3-BDA3-E9EE07A31C3F Q35072458-8F8E03E3-372B-4F8F-AD94-7EB1615C3D54 Q35108749-EA938F59-0A3B-43E7-AFF6-C63F512C0CAE Q35325376-D08C85E6-C54C-4D84-A9AF-555759AE1401 Q35666298-A5649DAE-9951-4F53-BB84-3F10A07895CA Q35857296-7195A61A-A96A-46D6-AC8A-FE068CE0B887 Q36072357-84AEA69E-CD7A-4F35-90A6-B3341B84E7B1 Q36093802-938FD1FD-DF72-48F2-AD86-2B897590398E Q36184322-C3E96249-617E-4B2E-9E98-0A401B40198D Q36245922-29071C32-BD0D-4F64-B839-23E9E3AE7512 Q36246124-F6EB2A2A-62E4-47E1-91B1-090DC1CE2139 Q36419309-B9CC77EC-DEE3-4A7C-BE9B-EB12E316F095 Q36511520-456F7146-E54D-47B8-9FED-C2A780E7377D Q36589381-DDC6EB49-6CFF-49E3-8055-ABA65C8CD052 Q36591533-EBA41ACD-E789-4FD1-A3F4-40E3D58AFC0B Q36633255-95460376-E95C-4D56-B571-E7B3A9611AA7 Q36673270-3A51B603-2BEB-4B3A-A855-856D2AD2FADB Q36690680-921D59D9-D31D-4708-8052-E63D343531DD Q36973719-51D926BD-C34C-4AE2-A148-59005DDEC973 Q37086713-58676EDE-E271-4E1A-A29C-6793F7CE5193 Q37305155-6B3F20FE-7761-4F46-858D-9CB7E8B04EF8 Q37340061-028E556E-EE73-483F-B759-B1C715142975 Q37386864-F75313DE-FC56-4FAF-BB43-2888FDBD5FBD Q37413166-87270C8A-B17B-4E56-A560-73D692B8B6C3 Q37443706-0D6E3B65-3962-48C3-870F-F9A22ADC910F Q37638268-5D356AC9-76B1-4516-B59B-833C55CECE60

P2860

Transforming growth factor beta as a therapeutic target in systemic sclerosis.

http://www.wikidata.org/entity/Q37428739

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Transforming growth factor beta as a therapeutic target in systemic sclerosis.

@en

Transforming growth factor beta as a therapeutic target in systemic sclerosis.

@nl

type

label

Transforming growth factor beta as a therapeutic target in systemic sclerosis.

@en

Transforming growth factor beta as a therapeutic target in systemic sclerosis.

@nl

prefLabel

Transforming growth factor beta as a therapeutic target in systemic sclerosis.

@en

Transforming growth factor beta as a therapeutic target in systemic sclerosis.

@nl

P1433

Q37428739-9DCB4616-0058-4949-81C1-E03433502AC5

P1476

Q37428739-2C5128C0-A3EF-40DE-AB29-B0E916E9B8D1

P2093

Q37428739-47A39C71-5117-47DA-A981-B6FE00CA61F7

Q37428739-9CBC09E5-53A5-44CF-BF3A-639793F813F6

P2860

Q37428739-001DC48F-0E94-4A89-A699-9D9E10755298

Q37428739-007192BA-11E2-4AE6-B88A-A57BCFE6A2BC

Q37428739-045C471B-06B9-4EE0-B112-DE0C0CA51A53

Q37428739-04F21AFA-6E65-413F-86D0-74733A04203B

Q37428739-0FE53090-9B02-40FD-8EEC-86D03D322671

Q37428739-15C28DFD-B86C-4E8B-96E6-8B92515A9DE3

Q37428739-1C667AD3-FC96-4245-BD9D-0129ABD2998E

Q37428739-1C817883-4B8D-4BD3-992C-196F37B52E88

Q37428739-1F658600-53D9-4EB9-BEB9-56043051CF08

Q37428739-20118156-FC22-4C5E-952C-79723B324AC5

P2888

Q37428739-B49A96C0-A1B2-4813-B6C9-F6775DDF4828

P304

Q37428739-33BA1EDD-5A75-433C-A666-AF2ED491083C

P31

Q37428739-6744C07D-527A-4062-9F0D-667C82B38E10

P356

Q37428739-AEEDFF4C-2B17-4444-A97E-699F2A0C9029

P407

Q37428739-28432DCA-00BE-4F14-BC04-970BE236CE4A

P433

Q37428739-34055DC9-AB9D-4654-B82F-32B2DD159EC2

P478

Q37428739-9FDB2AB7-4FBD-43A8-8932-D15FCC472345

P577

Q37428739-00EC37F7-C069-4869-AC2E-A4B66299838F

P698

Q37428739-94B07DBA-B9B0-4C39-8269-A714E10F16C5

P932

Q37428739-4E1AA066-9DF2-4ABE-BB28-9ECD98852D40

P356

NRRHEUM.2009.26

P1433

Nature Reviews Rheumatology

P1476

Transforming growth factor beta as a therapeutic target in systemic sclerosis.

@en

P2093

Boris Pasche

http://www.w3.org/2001/XMLSchema#string

John Varga

http://www.w3.org/2001/XMLSchema#string

P2860

PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling

Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome

Cellular and molecular mechanisms of fibrosis

Inhibition of transforming growth factor-beta1-induced signaling and epithelial-to-mesenchymal transition by the Smad-binding peptide aptamer Trx-SARA

Paclitaxel modulates TGFbeta signaling in scleroderma skin grafts in immunodeficient mice.

The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis

Role of transforming growth factor beta in human disease

Smad-dependent and Smad-independent pathways in TGF-beta family signalling

Making sense of latent TGFbeta activation

Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo

P2888

nrrheum.2009.26

P304

200-206

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRRHEUM.2009.26

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2009-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19337284

http://www.w3.org/2001/XMLSchema#string

P932

3959159

http://www.w3.org/2001/XMLSchema#string